News

Findings from a retrospective cohort study highlighted the impact of bariatric surgery on postoperative ocular disease incidence, reducing the risk of future ocular morbidity.

Household primary language was associated with vision screening, with children from non-English households exhibiting lower rates of pediatric vision screening.

The 3-year and 5-year renal survival rates did not exhibit significant changes, but IgAN's 10-year renal survival has shown gradual decreases since the 1990s.

New data shows one-quarter of patients with kidney disease associated with IBD progress to end-stage disease, with primary determinants including age and baseline eGFR.

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

Investigators reported that AI programs such as LightGBM could potentially significantly benefit the diagnosis of Berger disease.

Advanced kidney disease, type 2 diabetes, and high risk of disease progression were prevalent among the cohort based on records collected from the HealthVerity database.

In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.

Per the FDA, Kilitch Healthcare India Limited voluntarily recalls 27 eye drop items, including those distributed by CVS, Rite Aid, and Target, due to potential safety issues.

Results highlighted an association between socioeconomic deprivation and greater risk of progression to kidney failure in patients with IgAN.

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.

A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.

A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.

On November 15, 2023, the FDA approved Defencath. The new drug can reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.

The study revealed that patients meeting fibromyalgia criteria or displaying fibromyalgia-like symptoms were less likely to meet standardized response criteria with biologic therapy.

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.

Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Sent on November 13, 2023, the FDA letter warns Amazon on the introduction of unapproved new eye drop products into interstate commerce on their website.

Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.

The study author discusses the impact of findings showing MASH resolution without worsening fibrosis is a surrogate endpoint for 15-year bariatric surgery survival.

Ryan DeMasi, MD, explained the direct and indirect effects of upadacitinib and adalimumab on pain in patients with rheumatoid arthritis.

Viet Le, DMSc, PA-C, discusses early data from the Target-D trial and how this might influence the way he interprets the findings from other vitamin D supplementation studies.

At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.